

Bulley, Margaret

From: labclientservice
Sent: Thursday, March 22, 2018 12:36 PM
To: GME PC; Ortolf, Barbara; Salvatore, Alicia; Regional Physician Group Physicians; Regional Physician Group Practice Managers; Regional Physicians Group Directors of Operations; CPUP DOO's; CPUP Business Administrators; CPUP Managers
Cc: Fogt, Franz; Atweh, Mahmoud (Michael); Hunt, William; Wang, Ping (HUP Path and Lab); __Rulander, Nichole; Nachamkin, Irving; Mincarelli, Deborah; Bulley, Margaret; Danoski, Daniel; McLaughlin, Cara; __Leonard, Sarah; Long, Jeff; Acker, David; Agront, Sarita; Bahar, Wael Y; Mcaleer, Diane S; Macchione, Gerald; Kim, Sharon; Metheny, Robert
Subject: Penn Medicine - Aldolase memo
Attachments: aldolase_March272018v2.docx



Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Pennsylvania Hospital
Penn Presbyterian Medical Center

TO: UPHS Physicians and Staff

FROM: Department of Pathology and Laboratory Medicine
Ping Wang, Ph.D., DABCC, FACB, Director of Clinical Chemistry and Core Laboratory

SUBJECT: Aldolase

Effective March 27, Aldolase testing will transition from send-out laboratory ARUP to in-house testing in the Core Laboratory. Aldolase is a non-specific biomarker used in the diagnosis and monitoring of early stage acute hepatitis or primary skeletal muscle diseases. The same quantitative enzymatic methodology will be used in the Core Laboratory as in the send-out laboratory. No significant shift or bias in the results has been observed in the validation study. Reference range for patients 18 years or older is 1-8 U/L. The test is available as an orderable in PennChart (ALDOLASE [C9010004]).

Please direct any questions related to clinical correlation and interpretation to Dr. Ping Wang (Ping.Wang2@uphs.upenn.edu), or test ordering and reporting to Nichole Rulander (Nichole.Rulander@uphs.upenn.edu). Thank you.

Ping Wang, PhD, DABCC, FACB
Director of Clinical Chemistry and Core Laboratory